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Abstract
Background: Obesity is a growing health issue in the Western world. Obesity, as part of the
metabolic syndrome adds to the morbidity and mortality. The incidence of diabetes and
hypertension, two primary etiological factors for chronic renal failure, is significantly higher with
obesity. We report a case with morbid obesity whose renal function was stabilized with aggressive
management of his obesity.
Case report: A 43-year old morbidly obese Caucasian male was referred for evaluation of his
chronic renal failure. He had been hypertensive with well controlled blood pressure with a body
mass index of 46 and a baseline serum creatinine of 4.3 mg/dl (estimated glomerular filtration rate
of 16 ml/min). He had failed all conservative attempts at weight reduction and hence was referred
for a gastric by-pass surgery. Following the bariatric surgery he had approximately 90 lbs. weight
loss over 8-months and his serum creatinine stabilized to 4.0 mg/dl.
Conclusion: Obesity appears to be an independent risk factor for renal failure. Targeting obesity
is beneficial not only for better control of hypertension and diabetes, but also possibly helps
stabilization of chronic kidney failure.
Background
Obesity is a major health problem in the western world.
Nearly two-thirds of the U.S. adults are overweight (BMI >
25) and of these one-half are obese (BMI >30) [1]. Obes-
ity is not only associated with increase in morbidity, mor-
tality and reduction in life expectancy [2], but also leads
to increase in the incidence of diabetes [3], hypertension
[4], dyslipidemia and coronary artery disease [5]. Both
diabetes and hypertension together account for approxi-
mately 70% of end-stage renal disease (ESRD).
Approximately 300,000 adult deaths in the United States
each year are attributable to unhealthy dietary habits and
physical inactivity or sedentary behavior, with obese indi-
viduals having a 50 to 100 percent increased risk of death
from all causes; most of the increased risk is due to cardi-
ovascular causes [6,7]. Obesity has also resulted in an
increase in the cluster of disorders often referred to as the
"metabolic syndrome". Although kidney disease has not
yet been recognized as a major component of this meta-
bolic syndrome, accumulating evidence suggests that even
in non-diabetic obese patients, there is some degree of
renal dysfunction that can lead to more serious injury to
Published: 15 June 2005
BMC Nephrology 2005, 6:7 doi:10.1186/1471-2369-6-7
Received: 14 January 2005
Accepted: 15 June 2005
This article is available from: http://www.biomedcentral.com/1471-2369/6/7
© 2005 Agnani et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Nephrology 2005, 6:7 http://www.biomedcentral.com/1471-2369/6/7
Page 2 of 4
(page number not for citation purposes)
the kidneys as metabolic and hemodynamic disturbances
worsen with prolonged obesity [8,9].
We report a case that illustrates the stabilization of renal
function with obesity directed therapy.
Case Report
A 43-year-old Caucasian male was referred to the nephrol-
ogy clinic at Overton Brooks VAMC by his primary care
practitioner, in November of 2002 for management of his
chronic kidney disease. He was asymptomatic. His BP was
well controlled at 115/83 mmHg. He was morbidly obese
with a body mass index (BMI) of 46, chronic kidney dis-
ease stage 4 (MDRD GFR of 16 ml/min), non insulin
dependant diabetes mellitus, hypertension, coronary
artery disease status post stent placement and hyperlipi-
demia. His medications included nifedipine, fosinopril,
atenolol, rosiglitazone, furosemide, simvastatin, aspirin,
glyburide and calcium carbonate. Laboratory results:
Serum creatinine 4.3 mg/dl, BUN 54 mg/dl, normal elec-
trolytes, serum calcium 8.8 mg/dl, serum phosphorus 4.9
mg/dl, random urine protein 292 mg/dl, random urine
creatinine 49 mg/dl, urine protein/creatinine ratio of 5.9,
hemoglobin A1c 7% and hemoglobin 13.9 g/dl. Patient
was educated about the course and prognosis of his kid-
ney disease and advised diet and exercise for weight loss.
He was referred for arterial-venous fistula placement for
providing renal replacement therapy in future. Over the
next 6 months the patient failed all conservative methods
of weight loss including the use of orlistat. His morbid
obesity posed a major contraindication for enrolling him
for kidney transplantation. He agreed to the surgical ther-
apy option for treating his obesity. He was referred for bar-
iatric surgery in June 2003.
After the bariatric surgery in September 2003, he had lost
60 pounds at 6 months (BMI 37). He was able to discon-
tinue all his oral hypoglycemic agents maintaining a
hemoglobin A1c of 6.2% and required only one anti-
hypertensive medication to achieve the recommended tar-
get blood pressure reading. His BUN and creatinine has
remained at 22 mg/dl and 4.6 mg/dl respectively. The
patient is being followed at regular intervals and over the
course of the next eight months has lost an additional 30
pounds (BMI 32), a total weight loss of 90 pounds since
the bariatric surgery. His serum creatinine has remained
stable at 4 mg/dl, BUN 37 mg/dl, random urinary protein
99 mg/dl, random urinary creatinine 121 mg/dl, urine
protein/creatinine ratio of 0.8 and hemoglobin A1c 5.1%.
The inverse creatinine to time plot as shown in figure 1
clearly demonstrates the stabilization of the renal func-
tion 15 months following his weight loss surgery. The
patient was being evaluated for pre-emptive renal trans-
plantation and because of his previous history of coronary
artery disease he underwent a left heart catheterization
study in March 2005. Unfortunately, despite all precau-
tions he developed radio-contrast induced nephropathy
and had to be initiated on renal replacement therapy. He
currently remains on dialysis and is awaiting a renal trans-
plantation, which would not have been possible without
his weight loss.
Discussion
The case report presented here illustrates the benefits of
weight reduction on the progression of kidney disease.
There are few studies investigating the pathophysiology of
obesity and its early effects on kidney structure and func-
tion. Clinical as well as laboratory animal studies have
suggested the role of glomerular hypertension due to
renal vasodilatation and increase in hydrostatic pressure
leading to increased glomerular wall stress and increased
tubular sodium absorption [10,11]. The other proposed
mechanism of excessive tubular sodium re-absorption
include increased intra-renal pressures caused by the
excess accumulation of adipose tissue in the viscera with
compression of the loop of Henle and vasa recta leading
to sluggish flow in the renal tubules and vasa recta and
thus causing an increase in the tubular sodium re-absorp-
tion [9,12]. Increased sodium re-absorption in the loop of
Henle initially reduces the macula densa sodium chloride
delivery thereby initiating a macula densa feedback that
causes vasodilatation of afferent arterioles; this increases
renin secretion despite sodium retention and volume
expansion. The compensatory vasodilatation of afferent
arterioles resulting in an initial rise in glomerular filtra-
tion rate (GFR) and increase in the glomerular wall stress
leads to increased extra cellular matrix formation and
fibrosis along with injury to the kidneys and nephron loss
with a resultant decrease in GFR over a prolonged period
of time.
There is also a growing body of evidence that obesity per
se is a pro inflammatory state. Obesity is associated with
increased levels of acute phase reactants, and cytokines as
well as reactive oxygen species [13,14]. Glomerular hyper-
filtration also causes loss of protein in urine, which pro-
motes glomerular inflammatory responses thus leading to
progression of chronic kidney disease. In the already pre-
existing pro-inflammatory state of obesity this could have
an additive effect.
Proteinuria seen in obese patients is often considered to
be secondary to focal and segmental glomerulosclerosis.
However, Kambham et al have reported a distinct obesity
related histopathological change in the glomeruli,
referred to as obesity-related glomerulopathy and was
characterized by glomerulomegaly and focal segmental
glomerulosclerosis. This entity defers from idiopathic
focal segmental sclerosis with a lower incidence of neph-
rotic syndrome, more indolent course, consistentBMC Nephrology 2005, 6:7 http://www.biomedcentral.com/1471-2369/6/7
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presence of glomerulomegaly, and milder foot process
fusion [15].
We did not perform a renal biopsy hence we do not know
whether proteinuria was secondary to obesity related
glomerulopathy or idiopathic focal segmental sclerosis.
Adequate treatment of obesity reduces proteinuria and
decreases the need for medications such as angiotensin
converting enzyme inhibitors or angiotensin-receptor
blockers, which are known to further reduce the glomeru-
lar filtration rate.
Hence targeting obesity should benefit in maintaining
and preserving kidney function, regardless of whether
weight reduction is achieved by diet and exercise or by
bariatric surgery. Even though there have been no large
studies directly comparing the effectiveness of different
methods of weight loss on progression of kidney dysfunc-
tion, there is little doubt that weight loss reduces hyper-
tension and type 2 diabetes, the two main risk factors for
development of end stage renal disease. Bariatric surgery
is a rapidly evolving branch of surgical science with the
aim to induce major weight loss in those whose obesity
places them at high risk of serious health problems. Bari-
atric surgery leads to withdrawal of anti-diabetic therapy
in about 60% of patients, and reduction of therapy for
many other diabetic patients. Eighty-two percent of the
165 type-2 diabetes mellitus patients in the uncontrolled
observational study by Greenville achieved target glyc-
emic control without any medications after an average of
14-years follow up [16]. The SOS study was a well-
designed prospective study on obese patients in which,
bariatric surgery was compared with a non-surgical group.
The glycemic control without medication after 2-years in
the surgical group was achieved in twice the number of
patients compared to the control group [17].
Alexander et al studied 30 morbidly obese patients; 19
with chronic kidney disease and 11 with renal transplan-
tation; and reported gastric bypass surgery to be an effec-
tive means for achieving significant long-term weight loss
and relief of co-morbid conditions in patients with renal
failure on dialysis, in preparation for transplantation, or
after transplantation [18].
The above observations that bariatric surgery leads to
reduction in the risk factors associated with development
of ESRD and our case report showing that the progression
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of CKD was retarded with postponement of dialysis raises
the question: Should bariatric surgery be recommended in
the morbidly obese who fail to achieve sufficient weight
loss using non-surgical approaches especially those who
are young and have other metabolic syndrome risk factors
and are at a favorable anesthetic/surgical risk?
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